PTPA and leukemia: Several experimental flaws regarding Lai et al. (2018) study have been brought to light, including the choice to use cell lines and not primary normal and leukemia stem cells resistant to TKIs, the evaluation of cell viability rather than apoptosis and the lack of data regarding the translatability of PP2A inhibitors into clinical settings due to expected serious adverse events.